Importantly, targeted inhibition of EGFR and/or MET does not affect FER expression (Supplemental Fig. 6A), suggesting that FER may sustain invasive tumor growth independently of specific GFR antagonism. The gene discussed is RAPGEF5; the disease is neoplasm.